- Home
- ALDX vs FATE Comparison
ALDX vs FATE Comparison
Compare ALDX & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALDX | FATE |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.9M | 125.6M |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ALDX | FATE |
|---|---|---|
| Price | $1.48 | $2.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $5.50 | $4.10 |
| AVG Volume (30 Days) | 1.0M | ★ 1.9M |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.43 | 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.07 | $0.93 |
| 52 Week High | $6.18 | $3.23 |
Technical Indicators
Market Signals| Indicator | ALDX | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 35.86 | 48.00 |
| Support Level | $1.07 | $1.01 |
| Resistance Level | $1.88 | $3.22 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 46.83 |
Price Performance
Historical ComparisonAbout ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.